A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer

被引：0
|
作者：
Bangyou Zuo
Xiaobo Yang
Xu Yang
Jin Bian
Junyu Long
Dongxu Wang
Cong Ning
Yanyu Wang
Ziyu Xun
Yunchao Wang
Xin Lu
Yilei Mao
Xinting Sang
Haitao Zhao
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC),Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Gallbladder cancer; PD-1; Lenvatinib; PD-L1 expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1889 / 1896
页数：7
相关论文
共 50 条
  • [21] Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
    Li, Xiaowei
    Fu, Zhigang
    Chen, Xiaoxia
    Cao, Kunkun
    Zhong, Jiaming
    Liu, Li
    Ding, Ning
    Zhang, Xiaoli
    Zhai, Jian
    Qu, Zengqiang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] Efficacy and safety of anti-PD1 agents in patients with advanced GI malignancies: Real-world data
    Montenegro Luis, S.
    Garcia-Torralba, E.
    Vicente Conesa, M.
    Ricote Sanchez, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S80 - S80
  • [23] Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
    Shimozato, Naotaka
    Namisaki, Tadashi
    Okano, Akihiro
    Ohana, Masaya
    Kinoshita, Daisuke
    Kawasaki, Toshihiko
    Aihara, Yosuke
    Nakatani, Toshiya
    Kinoshita, Hiroki
    Ann, Tatsuichi
    Saito, Ko
    Yoshida, Motoyuki
    Yoshiji, Hitoshi
    ANTICANCER RESEARCH, 2022, 42 (01) : 173 - 183
  • [24] Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis
    Jiashuo Chao
    Shanshan Wang
    Hao Wang
    Nan Zhang
    Yunchao Wang
    Xu Yang
    Chengpei Zhu
    Cong Ning
    Xinmu Zhang
    Jingnan Xue
    Longhao Zhang
    Mingjian Piao
    Mingming Wang
    Xiaobo Yang
    Ling Lu
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 2023, 72 : 3717 - 3726
  • [25] Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma:A retrospective,real-world study conducted in China
    Dong-Xu Wang
    Xu Yang
    Jian-Zhen Lin
    Yi Bai
    Jun-Yu Long
    Xiao-Bo Yang
    Samuel Seery
    Hai-Tao Zhao
    World Journal of Gastroenterology, 2020, (30) : 4465 - 4478
  • [26] Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
    Wang, Dong-Xu
    Yang, Xu
    Lin, Jian-Zhen
    Bai, Yi
    Long, Jun-Yu
    Yang, Xiao-Bo
    Seery, Samuel
    Zhao, Hai-Tao
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (30) : 4465 - 4478
  • [27] The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
    Shuntaro Obi
    Takahisa Sato
    Shinpei Sato
    Miho Kanda
    Yuta Tokudome
    Yuichiro Kojima
    Yoji Suzuki
    Kenji Hosoda
    Toshihiro Kawai
    Yuji Kondo
    Yoshihiro Isomura
    Hiroshi Ohyama
    Keiko Nakagomi
    Hiroshi Ashizawa
    Yuko Miura
    Hiroyuki Amano
    Hitoshi Mochizuki
    Masao Omata
    Hepatology International, 2019, 13 : 199 - 204
  • [28] The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
    Obi, Shuntaro
    Sato, Takahisa
    Sato, Shinpei
    Kanda, Miho
    Tokudome, Yuta
    Kojima, Yuichiro
    Suzuki, Yoji
    Hosoda, Kenji
    Kawai, Toshihiro
    Kondo, Yuji
    Isomura, Yoshihiro
    Ohyama, Hiroshi
    Nakagomi, Keiko
    Ashizawa, Hiroshi
    Miura, Yuko
    Amano, Hiroyuki
    Mochizuki, Hitoshi
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2019, 13 (02) : 199 - 204
  • [29] Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer
    Ma, Ji
    Yao, Nan
    Lu, Jiaying
    Qu, Wanxi
    Cui, Li
    Yuan, Shiwang
    Li, Na
    Tong, Shaodong
    Qin, Zhaohui
    Yao, Yuanhu
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] A real-world study of vemurafenib plus anti-PD-1 antibody in Chinese patients with advanced BRAF V600-mutant melanoma
    Wen, X.
    Zhang, X.
    Li, D.
    Li, J.
    Ding, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S751 - S752
12345